Tap, W., Papai, Z., van Tine, B., Attia, S., Ganjoo, K., Jones, R. L., … Schoffski, P. (2016). Randomized phase 3, multicenter, open-label study comparing evofosfamide (Evo) in combination with doxorubicin (D) vs. D alone in patients (pts) with advanced soft tissue sarcoma (STS): Study TH-CR-406/SARC021. Annals of Oncology, 27, vi483. https://doi.org/10.1093/annonc/mdw388.01

Tap, W., Z. Papai, B. van Tine, S. Attia, K. Ganjoo, R. L. Jones, S. Schuetze, et al. “Randomized phase 3, multicenter, open-label study comparing evofosfamide (Evo) in combination with doxorubicin (D) vs. D alone in patients (pts) with advanced soft tissue sarcoma (STS): Study TH-CR-406/SARC021.” Annals of Oncology 27 (October 1, 2016): vi483. https://doi.org/10.1093/annonc/mdw388.01.

Tap W, Papai Z, van Tine B, Attia S, Ganjoo K, Jones RL, et al. Randomized phase 3, multicenter, open-label study comparing evofosfamide (Evo) in combination with doxorubicin (D) vs. D alone in patients (pts) with advanced soft tissue sarcoma (STS): Study TH-CR-406/SARC021. Annals of Oncology. 2016 Oct 1;27:vi483.

Tap, W., et al. “Randomized phase 3, multicenter, open-label study comparing evofosfamide (Evo) in combination with doxorubicin (D) vs. D alone in patients (pts) with advanced soft tissue sarcoma (STS): Study TH-CR-406/SARC021.” Annals of Oncology, vol. 27, Oct. 2016, p. vi483. Scopus, doi:10.1093/annonc/mdw388.01.

Tap W, Papai Z, van Tine B, Attia S, Ganjoo K, Jones RL, Schuetze S, Reed D, Chawla SP, Riedel R, Krarup-Hansen A, Italiano A, Hohenberger P, Grignani G, Cranmer L, Alcindor T, Lopez-Pousa A, Pearce T, Kroll S, Schoffski P. Randomized phase 3, multicenter, open-label study comparing evofosfamide (Evo) in combination with doxorubicin (D) vs. D alone in patients (pts) with advanced soft tissue sarcoma (STS): Study TH-CR-406/SARC021. Annals of Oncology. 2016 Oct 1;27:vi483.